Companies · ISRG
Intuitive Surgical
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Jul 21, 2026
Intuitive Surgical posts 19% revenue growth in Q2 2026 as da Vinci 5 adoption accelerates and IEEPA tariff refunds lift margins.
Intuitive Surgical delivered $2.89 billion in Q2 2026 revenue, driven by 15% da Vinci procedure volume growth and 246 da Vinci 5 placements — up from 180 in Q2 2025 — with the da Vinci 5 ASP mix pushing average system selling price to approximately $1.59 million versus $1.50 million a year ago. Gross margin expanded to 67.8% from 66.3%, aided by $35.9 million in IEEPA tariff refunds recognized in the quarter, partially masking $20.8 million in tariff costs still flowing through cost of revenue. A new risk factor on third-party remanufactured instruments signals a structural threat to the high-margin instruments and accessories revenue stream that represents 60% of total revenue.
Tone: bullishRevenue
$10.1B
ISRG 10-K · FY 2025
Employees
17,021
Revenue FY2024
$8.4B
Founded
1995
Profile
ISRG 10-K Item 1 · Feb 3, 2026Intuitive Surgical designs, manufactures, and markets robotic-assisted surgical and diagnostic systems, led by the da Vinci surgical system and the Ion endoluminal system. The company sells systems, instruments and accessories, training, and digital services to hospitals and healthcare systems worldwide. Its business model generates recurring revenue through procedure-driven instrument and accessory consumption and service contracts on an installed base exceeding several thousand systems globally.
Read filing description ↓ Collapse description ↑
As part of Intuitive's mission, we believe that minimally invasive care is life-enhancing care. By combining ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints. We envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly so patients can get back to what matters most. Since our founding over 30 years ago, we have been delivering on this mission and vision by combining innovative technology with clinical expertise to advance minimally invasive care. We do so by providing a comprehensive ecosystem that includes robotic-assisted systems, instruments and accessories, customer learning, and customer support services all connected by a digital portfolio that enables actionable insights across the care continuum. Among other capabilities, these products and services can augment the skills and improve the efficiency of clinicians and care teams while providing decision support and learning that can help deliver differentiated clinical and economic value for patients, providers, and payers when compared to the next best available treatment options. To assure continued alignment with the patients and healthcare community we serve, we have adopted the Quintuple Aim as our 'north star.' Starting with a focus on patients, we seek to demonstrate that our products can deliver better outcomes that are validated by rigorous, independent, and peer-reviewed evidence. We aim to create better patient experiences, enable care teams to have better experiences, help lower the total cost of care per patient episode, and expand access to high-quality minimally invasive care by working together with hospitals, healthcare systems, patient advocacy groups, and other stakeholders.
Primary products
- da Vinci 5 surgical system
- da Vinci Xi surgical system
- da Vinci X surgical system
- da Vinci SP surgical system
- da Vinci Si surgical system
- Ion endoluminal system
Business segments
End markets
Geographies
Named competitors
“We believe that the entrance or emergence of competition validates MIS and robotic-assisted surgery or robotic-assisted bronchoscopy.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenue grew from $8,352.1 million in 2024 to $10,064.7 million in 2025, driven by growth in both product and service revenue.
The rest of ISRG is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.